GLP-1 Link to Nail Detachment Collapses in New-Onset Data

Dr Dray

Surging reports of nail detachment among GLP-1 patients stem from preexisting medical conditions and nutritional shortfalls rather than direct drug toxicity, as the statistical association completely vanishes in new-onset cases.

AI-assisted summary of GLP-1s & Nail Detachment? New Study Reveals a Surprising Side Effect — original source. Check the original for full context.

Source published: 2026-10-07

Key ideas

An EADV study revealed that 39% of GLP-1 users reported onycholysis compared to 8.7% of non-users, alongside elevated rates of nail discoloration and general nail disorders. (1:28)
The apparent association between GLP-1s and nail detachment disappears (adjusted odds ratio drops to 0.9–1.0) when researchers restrict analysis strictly to new-onset cases that began after starting the medication. (2:54)
Onycholysis is commonly triggered by environmental factors or preexisting conditions frequent in GLP-1 candidates, including nail psoriasis, hypothyroidism, and fungal infections. (4:36)
Reduced food and fluid intake on GLP-1s places patients at elevated risk for nutritional deficiencies, including low iron, vitamin D, and B vitamins, though nail detachment itself is not a classic deficiency symptom. (9:40)
Patients experiencing nail lifting should consult a dermatologist rather than stopping their GLP-1 prescription, as abruptly discontinuing medication without medical supervision can carry adverse health risks. (12:45)

Detailed notes

## Background Published on YouTube by dermatologist Dr Dray on October 7, 2026, this video examines a newly presented study investigating a potential link between GLP-1 receptor agonists and nail disorders such as onycholysis. The description outlines the study's reported findings on nail detachment and discoloration, while highlighting major methodological limitations, nutritional considerations, and practical clinical guidance for patients.

## TL;DR Dr. Dray breaks down an international survey that initially reported a 39% rate of onycholysis among GLP-1 users compared to roughly 9% in non-users, cautioning that correlation does not mean causation. She demonstrates that nearly half of the affected patients had preexisting nail issues, and the statistical association completely disappeared when analyzing strictly new-onset cases after adjusting for confounders like underlying comorbidities and nutritional deficiencies. While rapid weight loss commonly triggers hair shedding, it does not typically detach nails; however, reduced appetite on GLP-1s can induce deficits in iron, B vitamins, and vitamin D. Ultimately, she advises patients not to panic or stop their medication abruptly, recommending a dermatologist visit with bare, unpolished nails for an accurate diagnosis.

## Atmosphere & style The video maintains a calm, analytical, and reassuring tone as Dr. Dray demystifies sensationalized headlines with clear dermatologic logic. Her delivery blends clinical rigor with casual, wry humor—complete with an amused snort when pointing out how the supposed risk vanishes in sub-analyses. Watching feels like sitting down for an evidence-based clinic consultation that de-escalates panic and replaces alarmism with sensible, practical medical advice.

## Bulletin - [01:28](https://www.youtube.com/watch?v=nGQggX1qajM&t=88s) An EADV study revealed that 39% of GLP-1 users reported onycholysis compared to 8.7% of non-users, alongside elevated rates of nail discoloration and general nail disorders. - [02:54](https://www.youtube.com/watch?v=nGQggX1qajM&t=174s) The apparent association between GLP-1s and nail detachment disappears (adjusted odds ratio drops to 0.9–1.0) when researchers restrict analysis strictly to new-onset cases that began after starting the medication. - [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) Onycholysis is commonly triggered by environmental factors or preexisting conditions frequent in GLP-1 candidates, including nail psoriasis, hypothyroidism, and fungal infections. - [09:40](https://www.youtube.com/watch?v=nGQggX1qajM&t=580s) Reduced food and fluid intake on GLP-1s places patients at elevated risk for nutritional deficiencies, including low iron, vitamin D, and B vitamins, though nail detachment itself is not a classic deficiency symptom. - [12:45](https://www.youtube.com/watch?v=nGQggX1qajM&t=765s) Patients experiencing nail lifting should consult a dermatologist rather than stopping their GLP-1 prescription, as abruptly discontinuing medication without medical supervision can carry adverse health risks.

## Key takeaways - [01:28](https://www.youtube.com/watch?v=nGQggX1qajM&t=88s) A multi-country cross-sectional study presented at the EADV examined nail and hair changes among 575 GLP-1 users versus 1,329 controls with obesity and/or type 2 diabetes. - [01:28](https://www.youtube.com/watch?v=nGQggX1qajM&t=88s) GLP-1 users in the study reported higher rates of onycholysis (39% vs. 8.7%) and nail discoloration (45.6% vs. 17%) compared to non-users. - [02:54](https://www.youtube.com/watch?v=nGQggX1qajM&t=174s) Nearly half of the GLP-1 users surveyed had preexisting nail conditions prior to initiating their medication, representing a critical confounding variable. - [02:54](https://www.youtube.com/watch?v=nGQggX1qajM&t=174s) Controlling for nutritional status and underlying health conditions reduced the adjusted odds ratio for onycholysis from 4.4 down to 2.9. - [02:54](https://www.youtube.com/watch?v=nGQggX1qajM&t=174s) When researchers analyzed strictly new-onset nail disorders arising after starting GLP-1 therapy, the statistical link completely vanished. - [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) Onycholysis occurs when the nail plate separates from the nail bed, creating an air pocket that appears as an opaque white patch. - [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) Routine external triggers such as aggressive manicures, moisture exposure from wet work, and fungal nail infections can cause onycholysis independently of medication. - [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) Preexisting systemic conditions strongly associated with obesity and diabetes, particularly nail psoriasis and hypothyroidism, frequently cause nail detachment and may be misattributed to GLP-1s. - [07:44](https://www.youtube.com/watch?v=nGQggX1qajM&t=464s) While rapid weight loss frequently triggers diffuse hair shedding via telogen effluvium, spontaneous nail detachment is not a recognized physiological consequence of weight loss. - [09:40](https://www.youtube.com/watch?v=nGQggX1qajM&t=580s) Marked appetite suppression and gastrointestinal side effects on GLP-1s can push individuals with poor baseline diets into frank nutritional deficiencies, such as iron, vitamin D, and B vitamins. - [11:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=696s) Patients noticing nail lifting should undergo clinical evaluation by a board-certified dermatologist and must remove all nail polish before the visit to allow proper inspection of the nail plate and bed. - [12:45](https://www.youtube.com/watch?v=nGQggX1qajM&t=765s) Patients should never abruptly discontinue a GLP-1 medication due to nail changes, and they should expect recovery to take several months due to slow nail growth.

## Detailed walkthrough ### [00:00](https://www.youtube.com/watch?v=nGQggX1qajM&t=0s) GLP-1 Medications and Reported Nail Changes

Dermatologist Dr. Dray opens by welcoming viewers back and acknowledging the growing public conversation around GLP-1 receptor agonists like semaglutide and tirzepatide. Prescribed widely for type 2 diabetes and chronic weight management, these medications have already been linked in dermatology circles to various dermatologic side effects, nutritional deficiencies, and noticeable hair shedding—topics she has covered in previous deep dives. However, she turns her attention to a newly surfaced, unexpected side effect that has raised eyebrows across the clinical community: significant nail changes.

A study presented at the European Academy of Dermatology and Venereology (EADV) highlighted an unusually high frequency of nail complaints among patients taking GLP-1 receptor agonists, occurring at rates far surpassing those seen in control patients living with obesity or diabetes who were not taking the drugs. The most startling headline finding was the prevalence of onycholysis—a condition where the hard nail plate lifts and separates from the vascularized nail bed underneath. The abstract reported that 39% of GLP-1 users experienced onycholysis compared to just 9% of non-users. While such numbers sound alarming at first glance, Dr. Dray immediately urges viewers not to panic or assume that starting a GLP-1 prescription will ruin their nails.

[01:28](https://www.youtube.com/watch?v=nGQggX1qajM&t=88s) Study Findings on Onycholysis and Nail Discoloration

To put the statistics into perspective, Dr. Dray breaks down the study's design and sample size. This was an international cross-sectional survey that gathered data from patients across four countries: the United States, France, Mexico, and Brazil. The researchers evaluated 575 individuals taking GLP-1 receptor agonists and compared them against a control cohort of 1,329 individuals diagnosed with obesity, type 2 diabetes, or both, who had never used a GLP-1 drug. Patients were asked directly about changes in their hair and nails, with investigators cataloging several distinct categories of nail abnormalities.

The primary figures showed that 39% of GLP-1 users experienced onycholysis, compared to only 8.7% in the control cohort, translating to an unadjusted 4.5-fold higher likelihood of nail plate detachment. Beyond nail lifting, researchers observed elevated rates of nail dyschromia (discoloration), reported in 45.6% of GLP-1 users versus 17% of controls—a 2.7-fold increase. Other commonly cited abnormalities included pronounced nail fragility and longitudinal or transverse nail ridges. When evaluating nail health broadly, 66% of GLP-1 users reported having some form of nail disorder, compared to 53% of participants in the control group.

- **Study Scope:** 575 GLP-1 users vs. 1,329 controls across the US, France, Mexico, and Brazil. - **Onycholysis Rate:** 39% in GLP-1 users vs. 8.7% in non-users (a 4.5-fold unadjusted increase). - **Nail Discoloration:** 45.6% in GLP-1 users vs. 17% in non-users (a 2.7-fold increase). - **Any Nail Disorder:** 66% in GLP-1 users vs. 53% in non-users.

[02:54](https://www.youtube.com/watch?v=nGQggX1qajM&t=174s) Correlation vs. Causation: Key Study Limitations

Dr. Dray emphasizes that observational study data must be interpreted with extreme caution and cannot prove that GLP-1 receptor agonists directly cause nail separation. This was not a prospective, randomized controlled trial where healthy nails were observed over time following a randomized intervention. In fact, a major confounding factor was present from the start: approximately half of the GLP-1 users in the study had a documented history of nail problems before ever initiating the medication.

When the researchers performed multivariable regression analyses to account for potential underlying causes—such as existing systemic medical conditions and nutritional deficiencies—the apparent strength of the association weakened substantially. For onycholysis, the adjusted odds ratio dropped from 4.4 (when adjusting only for age, sex, and country) down to 2.9 once nutritional deficits and underlying health conditions were factored in. For nail discoloration, the adjusted odds ratio declined from 3.3 to roughly 2.2.

The most telling finding emerged when researchers restricted their analysis exclusively to *new-onset* nail disorders that developed strictly after starting the GLP-1 medication. In that sub-analysis, the statistical association completely vanished: the adjusted odds ratio for nail discoloration plummeted to between 0.9 and 1.0. Dr. Dray reacts with an amused snort, noting that when you look strictly at new-onset cases, the data reveals no actual difference between GLP-1 users and non-users. This critical nuance underscores why flashy headlines often mislead patients into assuming causation where none exists.

```mermaid flowchart TD accTitle: Statistical Association Weakening Across Analytical Models accDescr: Flowchart illustrating how the adjusted odds ratio for nail problems declines as confounders are added and disappears for new-onset cases. subgraph Baseline["Initial Baseline"] A["Unadjusted / Demographic Adjustment<br/>(Age, sex, country)"] -->|"Onycholysis aOR: 4.4"| B["Strong Apparent Association"] end subgraph Multi["Multivariable Adjustment"] B -->|"Control for nutrition & comorbidities"| C["aOR drops to 2.9 (Onycholysis)<br/>aOR drops to 2.2 (Discoloration)"] end subgraph NewOnset["New-Onset Sub-Analysis"] C -->|"Exclude preexisting nail conditions"| D["Association Disappears<br/>(aOR ~0.9 - 1.0)"] end ```

[04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) Understanding Onycholysis and Common Confounders

To demystify the condition itself, Dr. Dray explains the anatomy of onycholysis. The nail plate is a dense, hard structure that normally adheres tightly to the underlying nail bed, where it receives vital nutrients and growth factors. When trauma, disease, or infection severs that bond, the nail plate lifts. Because air fills the newly formed pocket beneath the nail plate, the area reflects light and looks like an irregular, opaque "white blob" rather than healthy pink tissue.

Onycholysis has an extensive list of mundane and systemic triggers that have nothing to do with GLP-1 medications. Common mechanical and environmental causes include frequent manicures, aggressively scraping or picking under the nail margin, fungal nail infections (onychomycosis), and chronic moisture exposure from repeated hand-washing or "wet work" performed without protective gloves.

Furthermore, several major chronic illnesses are heavily linked both to onycholysis and to the patient populations who seek GLP-1 therapy: - **Psoriasis:** Nail psoriasis frequently causes onycholysis and pitting, and affected individuals face an increased risk of psoriatic arthritis in their hands. Because psoriasis is strongly linked to obesity and type 2 diabetes, these patients are naturally far more likely to be prescribed GLP-1s. Many individuals also have mild, undiagnosed psoriasis—brushing off isolated scaly patches as mere "dry skin" and ignoring occasional nail pits—meaning their nail changes predated the medication. - **Hypothyroidism:** Underactive thyroid disease frequently triggers nail brittleness, ridging, and detachment. Because thyroid dysfunction often contributes to weight management struggles and frequently coexists with type 2 diabetes, patients often receive GLP-1s while their thyroid-related nail symptoms are already underway. Dr. Dray describes these medications as simply being "guilty by association."

[07:44](https://www.youtube.com/watch?v=nGQggX1qajM&t=464s) The Role of Weight Loss and Telogen Effluvium

Dr. Dray addresses the logical follow-up question: could the rapid, profound weight loss induced by GLP-1 medications be triggering nail detachment? It is already well-documented that significant weight loss from any source—whether bariatric surgery, intense caloric restriction, crash diets, or GLP-1 therapy—can shock the body into a state of generalized hair shedding known as telogen effluvium.

In telogen effluvium, the body perceives rapid physiologic change or acute metabolic stress and triages its resources, thinking: *"Okay, we don't exactly know where things are going here, so why don't we conserve resources and not prioritize hair growth because it's not necessary for life."* Hair follicles are abruptly shifted out of their active growing phase into a resting, shedding phase, typically manifesting as heavy shedding roughly three months after the initial metabolic shock. Once body weight and metabolic demands stabilize, the follicles return to their normal growth cycle.

While it seems intuitive that the rapidly dividing matrix cells responsible for nail production might respond in the exact same way, Dr. Dray notes that nail physiology behaves differently. Unlike the hair shedding seen in telogen effluvium, dermatologists do not typically observe onycholysis (or spontaneous nail detachment) as a standard physiological consequence of acute weight loss, nor is it a standard presentation for underlying nutritional deficiencies, despite how common nutritional gaps can be in patients taking GLP-1 receptor agonists.

[09:40](https://www.youtube.com/watch?v=nGQggX1qajM&t=580s) Nutritional Deficiencies and GLP-1 Medications

Weight loss itself can impact nail appearance, but those alterations typically appear on the surface of the nail plate rather than causing separation from the bed. Dr. Dray emphasizes that people tend to blame weight loss exclusively for every physical change that arises on GLP-1 medications. However, evidence indicates that some systemic shifts are not merely downstream effects of dropping weight; these drugs alter multiple physiological processes, including lowering systemic inflammation.

Regardless of whether GLP-1 medications directly induce nail pathology, there is an established risk that demands attention: nutritional deficiencies. GLP-1 receptor agonists substantially suppress appetite and frequently trigger gastrointestinal side effects like nausea and stomach upset. As a result, patients consume substantially less food and often drink less fluid. Many individuals starting these medications were already "teetering on the edge" nutritionally; as Dr. Dray points out, it is remarkably easy to consume excess calories while eating a nutrient-poor diet. Entering treatment with borderline micronutrient reserves, followed by a dramatic drop in food intake, can easily tip someone into an overt deficiency state.

```mermaid flowchart TD accTitle: Nutritional Deficiency Risk on GLP-1 Medications accDescr: Flowchart illustrating how GLP-1 side effects combine with baseline dietary gaps to produce micronutrient deficiencies.

subgraph Baseline ["Baseline Status"] A["Caloric excess / nutrient-poor diet"] --> B["Borderline nutrient reserves"] end

subgraph GLP1Effects ["GLP-1 Medication Effects"] C["Marked appetite suppression"] D["Gastrointestinal upset & nausea"] C & D --> E["Significantly reduced food & fluid intake"] end

subgraph Outcome ["Clinical Result"] B & E --> F["Frank Nutritional Deficiencies"] F --> G["Iron deficiency"] F --> H["B vitamin deficiency (~3.2%)"] F --> I["Low vitamin D levels"] end ```

- Iron deficiency is particularly common among patients using GLP-1 therapies. - Research demonstrates that approximately 3.2% of studied patients develop a B vitamin deficiency. - Low vitamin D levels represent another prominent concern. - Many patients fail to reach the recommended daily allowances (RDAs) for key minerals and essential nutrients, placing them in an at-risk clinical category.

[11:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=696s) Clinical Evaluation of Detaching Nails

For anyone noticing that their nails are lifting or separating, consulting a board-certified dermatologist is the essential next step. Dermatologists manage far more than cosmetic procedures: "We don't just do Botox and fillers. We are the specialty that has expertise and training in diagnosis and management of nail disorders." A clinical evaluation is necessary because onycholysis stems from numerous possible triggers—including nail psoriasis or fungal infections—that must be systematically identified or ruled out.

Dr. Dray offers a practical, impassioned plea for clinic visits: never show up to a hard-earned dermatology appointment wearing nail polish. Polish completely conceals the nail bed, making an accurate examination impossible and wasting precious appointment time. Patients should avoid assuming a GLP-1 agonist is the direct culprit; while recent research highlights a statistical association, the underlying numbers do not demonstrate that the medication itself causes onycholysis.

- Schedule an evaluation with a board-certified dermatologist rather than attempting self-diagnosis. - Remove all nail polish prior to the appointment so the nail plate and bed can be thoroughly inspected. - Diagnostic evaluation helps distinguish drug side effects from common culprits like fungal onychomycosis or psoriasis.

[12:45](https://www.youtube.com/watch?v=nGQggX1qajM&t=765s) Treatment Decisions and Final Takeaways

Under no circumstances should patients abruptly discontinue a GLP-1 medication due to emerging nail abnormalities. Stopping prescription therapies without physician guidance can carry negative health consequences. The appropriate course of action is to have the nail condition formally assessed and managed while continuing prescribed regimens under medical oversight. Patients must also manage their expectations regarding recovery: because nails grow slowly, resolving nail plate separation and restoring normal attachment takes months of patience even after the underlying cause is addressed.

The recent study provides intriguing signals that GLP-1 users experience elevated rates of nail findings, but it leaves open whether the culprit is the drug molecule itself, rapid weight loss, or an unaddressed micronutrient deficit. Dr. Dray encourages viewers—many of whom take these agents for weight management, diabetes, or off-label indications—to share their personal experiences with onycholysis or nail changes in the comments. She directs viewers to a follow-up video detailing cutaneous warning signs of nutritional deficiencies seen during GLP-1 therapy, before signing off with her signature reminder: "don't forget sunscreen and subscribe."

## Notable quotes > [07:44](https://www.youtube.com/watch?v=nGQggX1qajM&t=464s) Okay, we don't exactly know where things are going here, so why don't we conserve resources and not prioritize hair growth because it's not necessary for life. — Dr. Dray

> [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) guilty by association — Dr. Dray

> [04:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=276s) white blob — Dr. Dray

> [09:40](https://www.youtube.com/watch?v=nGQggX1qajM&t=580s) teetering on the edge — Dr. Dray

> [11:36](https://www.youtube.com/watch?v=nGQggX1qajM&t=696s) We don't just do Botox and fillers. We are the specialty that has expertise and training in diagnosis and management of nail disorders. — Dr. Dray

> [12:45](https://www.youtube.com/watch?v=nGQggX1qajM&t=765s) don't forget sunscreen and subscribe — Dr. Dray

## Mentioned Dr. Dray, European Academy of Dermatology and Venereology, Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, tirzepatide

## Video description Could your nails be affected by GLP-1 medications such as Ozempic, Wegovy, Mounjaro, or Zepbound? Dermatologist Dr. Dray examines a new study investigating a potential link between GLP-1 receptor agonists and nail problems, including onycholysis, or separation of the nail from the nail bed. The study found that nail detachment and nail discoloration were reported more frequently among GLP-1 users than among people with obesity and/or type 2 diabetes who had never used GLP-1 medications. However, the findings do not prove that GLP-1 medications cause nail detachment. Dr. Dray explains the important limitations of the study, including the fact that nearly half of GLP-1 users reported nail problems before starting treatment and that the association disappeared when researchers looked specifically at new-onset nail abnormalities. The video also discusses GLP-1 medications, weight loss, nutritional deficiencies, and nail health, including research on vitamin D, iron, B vitamins, calcium, and overall dietary intake during GLP-1 treatment. Dr. Dray explains what onycholysis looks like, other common causes of nail separation, what to do if you notice your nails lifting from the nail bed, and whether you should stop a GLP-1 medication because of nail changes.

Related videos from Dr. Dray: Skin Benefits of GLP-1 Medications: Watch here Can Skincare Fix Ozempic Face? Watch here Nutritional Deficiencies From GLP-1 Medications: Watch here Ozempic Face & Aging Effects of GLP-1 Medications: Watch here GLP-1s and Hair Loss: Watch here Skin Benefits of GLP-1 Medications https://youtu.be/vESsyr2i6iA

Can Skincare Fix Ozempic Face? https://youtu.be/zURv_nMTUc0

Nutritional Deficiencies From GLP-1 Medications https://youtu.be/SXjwBXIZtvQ

Ozempic Face & Aging Effects of GLP-1 Medications https://youtu.be/E0V7jgubOfc

GLP-1s and Hair Loss https://youtu.be/0VW43kd63zM

TIMESTAMPS 0:00 GLP-1 medications and nail detachment 1:28 What did the study find? 2:54 Does this prove GLP-1s cause nail problems? 4:36 What is onycholysis? 7:44 Could weight loss cause nail changes? 10:07 Nutritional deficiencies and GLP-1 medications 11:36 What to do if your nail starts detaching 12:45 Should you stop your GLP-1 medication? 13:16 The bottom line

Important: This study found an association between GLP-1 receptor agonist use and reported nail disorders, but it does not establish that GLP-1 medications directly cause nail detachment. Anyone experiencing new or concerning nail changes should discuss them with a healthcare professional.

#GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #GLP1SideEffects #NailHealth #Onycholysis #NailChanges #NailDetachment #OzempicSideEffects #WegovySideEffects #MounjaroSideEffects #GLP1Medications #Dermatologist #DrDray #SkinHealth #NutritionalDeficiency

FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links.

💜Shop my Amazon store https://o.bttn.io/0BwiPWFIZLG 💜Follow me on liketoknowit https://www.liketoknow.it/drdrayzday 💜Social media Instagram @drdrayzday Pinterest https://www.pinterest.com/drdrayzday/ Facebook @DrDrayzDay Twitter: @drdrayzday Tiktok: @drdrayzday

Disclaimer: This video is not intended to provide diagnosis, treatment or medical advice. Content provided on this Youtube channel is for informational purposes only. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options. Information on this Youtube channel should not be considered as a substitute for advice from a healthcare professional. The statements made about specific products throughout this video are not to diagnose, treat, cure or prevent disease.

[Source](https://www.youtube.com/watch?v=nGQggX1qajM)

中文简报

新发数据推翻GLP-1与指甲脱落的关联 GLP-1使用者中指甲脱落报告的激增，源于原有的基础疾病和营养不足，而非药物的直接毒性，因为该统计学关联在新发病例中完全消失。 Dray医生对一项国际调查进行了深入分析。该调查最初报告称GLP-1使用者的甲剥离症发生率为39%，而非使用者仅约为9%，但她提醒相关性并不等于因果关系。她指出，近半数受影响的患者此前就存在指甲问题，而在排除了潜在共病和营养缺乏等混杂因素后，仅分析严格意义上的新发病例时，该统计学关联便完全消失了。尽管体重快速减轻通常会引发脱发，但通常不会导致指甲脱落；不过，使用GLP-1后食欲下降可能引起铁、B族维生素和维生素D的缺乏。最后，她建议患者切勿恐慌或擅自停药，并建议保持指甲素颜、不涂甲油前往皮肤科就诊，以获得准确诊断。 EADV的一项研究显示，39%的GLP-1使用者报告出现甲剥离症，而非使用者中该比例为8.7%，同时指甲变色和普遍指甲病变的发生率也有所上升。 (1:28) 当研究人员将分析严格限制在用药后才出现的新发病例时，GLP-1与指甲脱落之间表面上的关联便不复存在（调整后的比值比降至0.9–1.0）。 (2:54) 甲剥离症通常由环境因素或GLP-1适用人群中常见的既往疾病诱发，包括甲银屑病、甲状腺功能减退和真菌感染。 (4:36) 使用GLP-1导致食物和液体摄入减少，会使患者面临更高的营养缺乏风险（包括铁、维生素D和B族维生素偏低），但指甲脱落本身并不是典型的营养缺乏症状。 (9:40) 出现指甲翘起或脱落的患者应咨询皮肤科医生，而不应擅自停用GLP-1处方药，因为在没有医疗监督的情况下突然停药可能会带来健康风险。 (12:45)

Reading summary

Dermatologist Dr. Dray reviews an international survey linking GLP-1 receptor agonists to high rates of nail detachment, explaining that adjusting for preexisting conditions and nutritional deficits eliminates the statistical association for new-onset cases. Survey Data Links GLP-1 Use to Detachment (1:28) An international cross-sectional survey presented at the European Academy of Dermatology and Venereology evaluated 575 GLP-1 users against 1,329 non-user controls with obesity, type 2 diabetes, or both across the United States, France, Mexico, and Brazil. Unadjusted findings showed that 39% of GLP-1 users reported onycholysis—where the nail plate separates from the underlying nail bed—compared to 8.7% of controls, reflecting a 4.5-fold higher unadjusted likelihood. Researchers also documented elevated rates of nail discoloration, which affected 45.6% of GLP-1 users versus 17% of controls. Overall, 66% of GLP-1 users reported some form of nail abnormality, including nail fragility and ridging, compared to 53% in the control cohort. While the headline figures raised clinical concerns, Dr. Dray notes that the observational nature of the survey requires closer scrutiny. Confounders Dissolve the New-Onset Statistical Association (2:54) Dr. Dray emphasizes that observational surveys cannot establish direct causation, noting that approximately half of the GLP-1 cohort had documented nail issues prior to initiating therapy. When investigators performed multivariable regression accounting for baseline systemic health and nutritional deficits, the adjusted odds ratio for onycholysis decreased from 4.4 to 2.9, and the odds ratio for nail discoloration dropped from 3.3 to 2.2. The association weakened further when researchers analyzed only new-onset disorders that developed after starting the medication. In that subgroup, the adjusted odds ratio for nail discoloration fell to between 0.9 and 1.0, showing no meaningful statistical difference between GLP-1 users and controls. Dr. Dray points to this disappearance of risk as evidence that the medications do not directly cause nail separation. Mechanical Triggers and Overlapping Systemic Conditions (4:36) Onycholysis occurs when trauma, infection, or systemic illness separates the nail plate from the vascular bed, creating an air pocket that appears as an opaque white patch. Common mechanical triggers include manicures, aggressive scraping beneath the nail margin, fungal infections (onychomycosis), and chronic moisture from frequent hand-washing. Systemic conditions common in GLP-1 candidates frequently trigger nail changes independently. Nail psoriasis causes onycholysis and pitting, often predating treatment in patients managing diabetes or obesity. Hypothyroidism similarly causes ridging, brittleness, and detachment while contributing to metabolic struggles. Furthermore, Dr. Dray clarifies that while rapid weight loss regularly induces temporary hair shedding (telogen effluvium), acute weight reduction is not a known physiological trigger for onycholysis. Nutritional Risks and Clinical Management Guidelines (9:40) Although GLP-1s do not appear to cause direct nail detachment, Dr. Dray highlights that the drugs introduce genuine nutritional risks. Appetite suppression and gastrointestinal side effects like nausea significantly lower food and fluid intake, which can trigger overt deficiencies in patients starting with marginal micronutrient reserves. Documented concerns include iron deficiency, low vitamin D, and B vitamin deficiencies (reported in roughly 3.2% of patients). Patients noticing lifting nails are advised to consult a board-certified dermatologist to rule out psoriasis or fungal infections, and to remove nail polish before the visit to allow bed examination. Dr. Dray stresses that patients should never stop prescribed GLP-1 therapy without medical supervision, noting that repairing detached nail plates requires several months of slow nail regrowth. Dr. Dray concludes that while GLP-1 patients report disproportionately high rates of nail issues, the data points to confounding preexisting diseases, mechanical factors, or dietary deficits rather than direct pharmacological toxicity from the medications.

Source quotes

[7:44] Dr. Dray: Okay, we don't exactly know where things are going here, so why don't we conserve resources and not prioritize hair growth because it's not necessary for life. [4:36] Dr. Dray: guilty by association [4:36] Dr. Dray: white blob [9:40] Dr. Dray: teetering on the edge [11:36] Dr. Dray: We don't just do Botox and fillers. We are the specialty that has expertise and training in diagnosis and management of nail disorders. [12:45] Dr. Dray: don't forget sunscreen and subscribe

Original transcript

[0:00] Well, hey guys, welcome back. If you are [0:02] new here, my name is Dr. Dre and I'm a [0:04] board-certified dermatologist. If you're [0:07] taking a GLP-1 medication, such as [0:09] semaglutide or tirzepatide, say for our [0:12] weight management or diabetes, there's a [0:14] chance you have heard people talking [0:16] about different skin changes that can [0:18] arise in patients taking these [0:19] medications. Now, I already have a lot [0:21] of videos on my channel detailing all of [0:23] the different skin signs that we are [0:25] seeing in patients on GLP-1 medications, [0:28] as well as a deep dive on warning signs [0:31] and nutritional deficiencies that can [0:32] arise, and of course, the hair loss [0:35] issue. But, in today's video, I want to [0:37] talk about a new study that has brought [0:40] to everyone's attention a potential [0:41] interesting and unexpected association, [0:44] and that is nail changes in patients on [0:47] GLP-1 medications. A new study that was [0:49] presented at the European Academy of [0:51] Dermatology and the Neurology reported [0:53] an association of nail findings in [0:55] patients taking GLP-1 receptor [0:57] medications far and above what was ever [1:00] seen in patients with obesity and or [1:02] diabetes not taking these medications. [1:04] One nail finding in particular was [1:06] surprising and unexpected, and that is a [1:08] finding known as onycholysis, where the [1:10] nail plate separates from the underlying [1:13] nail bed. This finding was reported in [1:15] 39% of GLP-1 receptor medication users [1:19] in comparison to 9% of patients who [1:22] weren't on these medications. If you are [1:23] taking one of these medications, don't [1:26] panic and fear that your nails are going [1:28] to be wrecked. First of all, this was [1:30] international study that involved [1:31] patients not just in the United States, [1:33] but also France, Mexico, and Brazil. [1:36] There were 575 people taking GLP-1 [1:39] receptor medications. They were compared [1:41] to 1,329 [1:43] people who had obesity and or diabetes [1:46] who had never taken a GLP-1 medication [1:48] before. And the researchers were asking [1:50] patients about nail changes and hair [1:52] changes. They actually looked at several [1:54] different types of nail abnormalities, [1:56] and what they is that 39% of GLP-1 [1:59] medication users had onycholysis in [2:02] comparison to 8.7% in the control group. [2:05] So, that's a 4.5-fold higher likelihood [2:08] that your nail plate separates from the [2:10] underlying nail bed. In addition to [2:12] onycholysis, the researchers also found [2:14] more cases of nail discoloration and [2:17] nail dyschromia. Specifically, 45.6% of [2:20] GLP-1 receptor medication users versus [2:23] 17% of non-users. So, that's a 2.7-fold [2:27] higher likelihood that you have some [2:29] sort of nail color change. A lot of [2:31] patients also showed nail fragility and [2:34] nail ridges on GLP-1 medications. [2:36] Researchers then just looked in general [2:38] at any type of nail disorder, and 66% of [2:41] GLP-1 users had any nail disorder [2:44] compared to 53% in the control group. [2:47] But, we have to be very careful how we [2:49] interpret numbers. It doesn't [2:50] necessarily prove that GLP-1 medications [2:53] are causing the nail changes. Because [2:55] this was not a randomized control trial [2:56] where participants were randomized to [2:58] receive either GLP-1 medications or [3:01] control, and then their nails were [3:03] observed over time while they were on [3:05] the intervention. Half of people taking [3:07] a GLP-1 medication also had a prior [3:09] history of some sort of nail problem [3:11] prior to ever going on the drugs. The [3:13] researchers performed some additional [3:15] analyses to attempt to see if the nail [3:17] changes were tracking with any other [3:20] potential expected causes of these nail [3:23] changes, such as underlying medical [3:26] nutritional deficiencies. When those [3:28] particular factors were taken into [3:29] account, the association was smaller, [3:31] but it was still present. The adjusted [3:33] odds ratio for onycholysis went down [3:36] from 4.4 when adjusting for age, sex, [3:40] and country to about 2.9 when [3:43] nutritional deficiencies and underlying [3:44] medical conditions were taken into [3:46] account and considered. And for nail [3:48] discoloration, the adjusted odds ratio [3:50] went down from about 3.3 to roughly 2.2. [3:54] So, there was still an association. [3:56] Then, they started looking specifically [3:58] for new onset nail disease in GLP-1 [4:01] medication users, meaning the nail [4:03] abnormality appeared after the drug was [4:05] started. In that analysis, the [4:07] association basically disappeared. [4:10] >> [snorts] [4:10] >> The adjusted odds ratio went from 1 to [4:13] 0.9 for nail discoloration. So, in other [4:15] words, the data did not show a [4:17] difference between GLP-1 users and [4:20] non-users when they were just focusing [4:22] specifically on new onset of nail [4:24] disease, which is why you really need to [4:26] be careful when interpreting studies. [4:29] This study doesn't prove that GLP-1 [4:32] medications cause the nail plate to [4:34] detach from the underlying nail bed. [4:36] Speaking of which, what exactly is [4:39] onycholysis? What does it look like? Um [4:41] how do you know if you have this? I [4:42] actually have an older video all about [4:45] onycholysis and the many different [4:47] causes for it. But, what it is is the [4:49] nail plate, which is a hard structure, [4:52] um is normally attached to an underlying [4:54] nail bed where it receives uh growth [4:57] factors and nutrients. Certain [4:59] situations, medical illness, infections, [5:02] oftentimes, you can have a sudden [5:04] separation of the nail plate from the [5:06] underlying nail bed, and you get air [5:08] under the nail plate, and it looks like [5:11] just a white blob on the nail, but it's [5:13] actually air up under the nail plate. [5:15] There are many causes of onycholysis. [5:17] So, simply having this nail finding in [5:19] of itself may have absolutely nothing to [5:22] do with any medication you're on. It can [5:24] be the result of trauma or repeat [5:27] manicures. If you pick under your nails [5:29] or if you tend to have your nails [5:31] submerged a lot throughout the day and [5:33] water your hands in water, like you do a [5:35] lot of what we call wet work and you [5:36] don't wear gloves. Fungal nail [5:38] infections can also cause onycholysis, [5:40] and it's commonly commonly seen in [5:42] patients who have psoriasis. Patients [5:44] with psoriasis who have nail psoriasis, [5:47] nail changes, they're at a greater [5:49] likelihood of having arthritis in their [5:51] hands. So, it's important, in other [5:53] words, to tease this out. As you can [5:55] imagine, patients with psoriasis, not [5:57] only are they just more likely to have [5:59] onycholysis, but we already know there [6:01] is a strong um association with [6:03] psoriasis and obesity and type 2 [6:06] diabetes. And therefore, the likelihood [6:09] just for psoriasis alone that somebody [6:11] has psoriasis, has nail psoriasis, and [6:15] they're dealing with obesity and/or [6:17] diabetes, they're likely going to go on [6:19] these medications, which as a side note, [6:21] are showing a lot of promise for helping [6:24] psoriasis, probably because of some of [6:27] the weight management benefits, but [6:29] perhaps due to other metabolic things, [6:32] anti-inflammatory effects, but [6:33] nonetheless, this is a group of people [6:35] who oftentimes has these nail findings, [6:38] is what I'm getting at. A lot of people [6:39] may have this, um and they may have an [6:42] underlying cause that is unidentified. [6:44] In the case of psoriasis, some people [6:45] might actually have undiagnosed [6:47] psoriasis, okay? They maybe have a [6:49] little patch of psoriasis on their skin [6:51] here and there, and they just think it's [6:52] dry skin. But they have obesity or [6:54] diabetes, which goes along with [6:56] psoriasis. They maybe had some little [6:58] pits on their nails off and on [6:59] throughout their lifetime that sometimes [7:01] they notice. So, it's not out of the [7:03] realm of possibility for somebody to [7:04] have psoriasis and not even know about [7:07] it. And of course, there are underlying [7:08] systemic medical conditions, disease [7:10] states for which you can have [7:12] onycholysis, namely hypothyroidism. It [7:15] can cause a variety of nail changes, [7:17] including the nail ridges, as a side [7:19] note. For example, someone who has low [7:21] thyroid, they might also struggle with [7:23] weight management, and perhaps they may [7:25] also have type 2 diabetes. It's not [7:27] uncommon to have all three things going [7:29] on. The nail changes could be a [7:31] manifestation of their thyroid disease [7:33] and are simply uh you know, guilty by [7:35] association with the GLP-1, because [7:37] they're a group of people who are [7:39] possibly more likely to pursue this [7:41] medication for weight management or for [7:43] diabetes. Now, one of the most obvious [7:45] questions when it comes to a change like [7:48] this is, could this be related to weight [7:50] loss? We already know that patients who [7:52] experience profound weight loss by any [7:55] means, not just through these [7:56] medications, whether it be weight loss [7:58] surgery, whether it be diet, exercise, [8:00] or some sort of crash diet, patients who [8:02] have [8:03] a significant weight loss, they can [8:05] experience about of increased hair [8:07] shedding known as telogen effluvium. [8:10] That's already well established for [8:12] patients taking these because again, [8:13] they do lose a lot of weight. Telogen [8:15] effluvium is a state where your body [8:17] recognizes that a pretty significant [8:20] change is going on and it's like, "Okay, [8:21] we don't exactly know where things are [8:24] going here, so why don't we conserve [8:27] resources and not prioritize hair growth [8:30] because it's not necessary for life. [8:32] Instead, we're going to make sure that [8:34] everything else in the tank is [8:35] optimized." And so, what ends up [8:37] happening is you get a massive hair [8:39] shedding known as telogen effluvium, and [8:41] it typically occurs roughly 3 months [8:43] after the weight loss has begun to a [8:46] significant extent, and it can go on for [8:48] a long time. And then, once things [8:50] stabilize, the hair gets back into the [8:51] growing phase, and everything is as it [8:53] was in the past. You know, you don't [8:56] usually have to deal with it for [8:57] extended periods of time, and it can [8:59] happen secondary to other things, not [9:01] just weight loss, like having a fever, [9:04] being in a car accident, having a major [9:06] surgery, giving birth. There are so many [9:08] causes, but we're not going to belabor [9:10] the the talking points on telogen [9:12] effluvium, but rather, you may be [9:14] wondering, "Well, you know, that's [9:15] affecting these rapidly dividing cells. [9:18] Wouldn't something like that also lead [9:20] to nail shedding, you know, peeling up [9:22] of the nails off of the nail bed, [9:24] onycholysis?" We don't typically see [9:26] onycholysis like we see telogen [9:28] effluvium with weight loss, nor do we [9:31] typically see it with underlying [9:33] nutritional deficiencies, which as a a [9:35] note, are actually pretty common in [9:37] patients who are on GLP-1 medications. [9:40] Instead, weight loss associated nail [9:42] abnormalities are more commonly going to [9:44] be on the surface of the nail plate. I'm [9:46] pointing that out because I think the [9:48] tendency for everyone would be anything [9:50] that comes up with these medications is [9:52] to solely chalk it up to the weight [9:54] loss. But, we have some indications [9:57] elsewhere that some of the changes are [9:59] not simply related to the effects of the [10:01] drug on the weight. Cuz remember, these [10:02] medications they have a variety of other [10:05] effects throughout the body including [10:07] reducing inflammation. Regardless of [10:08] whether or not GLP-1 medications impact [10:10] the nail, there is another issue that is [10:12] definitely worth mentioning and that is [10:14] the risk of nutritional deficiencies in [10:17] patients who take GLP-1 medications. [10:19] They decrease appetite substantially. [10:22] They also can, as a side effect, produce [10:24] some nausea, some gastrointestinal [10:27] upset. Patients end up not only eating [10:29] significantly less, but they also end up [10:32] drinking less fluid. It's a scenario [10:34] where [10:35] who, in many cases, may already have [10:37] some teetering on the border [10:39] nutritional, not so great. It's pretty [10:42] easy to eat a caloric excess and have a [10:44] very nutrient poor diet, okay? So, you [10:47] can have obesity and you can have a [10:49] variety of sub optimal, we'll say, [10:52] levels of different nutrients. Then you [10:54] enter on one of these medications, you [10:55] lose a lot of weight because you stopped [10:57] taking in very much food. And so, you [10:59] can imagine where now things where you [11:01] were starting at kind of [11:03] teetering on the edge. [11:05] You get a nutritional deficiency. It's [11:07] not uncommon for these patients to [11:09] develop different nutritional [11:10] deficiencies. Iron deficiency is really [11:13] common and about 3.2% of patients [11:16] studied have also been shown to have a B [11:18] vitamin deficiency. There's also concern [11:21] for low vitamin D in these patients. [11:23] But, a lot of patients who are on these [11:25] medications do consume significantly [11:27] less than the recommended daily [11:29] allowances of different nutrients, [11:32] different minerals, etc. So, in other [11:34] words, yeah, they are an at-risk group. [11:36] What should you do if you start noticing [11:38] that your nails are detaching? Well, I [11:40] strongly encourage, whether or not you [11:42] are taking one of these medications or [11:44] not, see a board-certified [11:45] dermatologist. We don't just do Botox [11:47] and fillers. We are the specialty that [11:50] has expertise and training in diagnosis [11:53] and management of nail disorders. And [11:55] so, we will be able to best evaluate [11:57] your nails. When you see a [11:59] dermatologist, do not waste your [12:01] precious time in that challenging to get [12:05] appointment slot by showing up with nail [12:06] polish on because they cannot properly [12:09] examine your nails with nail polish on. [12:11] So, make sure you don't go to the [12:12] dermatologist with nail polish on, okay? [12:15] But, they can take a careful look [12:17] because, like I indicated earlier, there [12:20] are many causes of onycholysis. Fungal [12:22] infection, definitely want to rule that [12:24] out. Psoriasis, all sorts of things. So, [12:26] that would be my recommendation before [12:28] just seeing that and being like, "Oh my [12:30] gosh, this is the medication." Because [12:32] this study, while it identified this [12:34] association, it suggests that it's not [12:37] actually the drug itself impacting the [12:40] onycholysis. Because, I mean, it could, [12:43] but the numbers aren't really supporting [12:46] that. Should you stop taking your GLP-1 [12:48] medication because you're concerned [12:50] about nail changes? No, don't ever just [12:52] stop taking a medication without talking [12:55] to your healthcare provider first [12:57] because there can be consequences to [13:00] just abruptly stopping a medication. A [13:02] better use of your time resources is to [13:05] have a nail problem evaluated. And [13:07] remember, nails take time to grow. So, [13:09] don't be surprised if it takes a long [13:11] time for this to go back to normal once [13:14] you have identified the cause and [13:15] treated it appropriately. Bottom line [13:18] is, this is interesting. It suggests [13:20] that GLP-1 medication users may be [13:23] having some interesting nail findings. [13:26] Whether it's related to the medication [13:27] or not, we can't say. Whether it's [13:29] related to weight loss or not, really [13:31] can't say um per se or a specific [13:34] nutrient deficiency, but it's definitely [13:36] worth more research and ongoing [13:38] investigation. But let me know in the [13:40] comments uh cuz I know a lot of you guys [13:42] take these medications. They're very [13:44] common nowadays. Lots of people take [13:46] them for various uh reasons even, not [13:49] just weight management or obesity. They [13:51] may be taking them off label. Have you [13:52] noticed any nail changes or do you have [13:55] have you ever experienced onycholysis? [13:57] Share in the comments below. I hope you [13:59] guys enjoyed today's video. On the end [14:01] slide, I'm going to put the thumbnail, [14:03] which you can tap on to take you to the [14:04] video, which is going to share with you [14:06] guys skin warning signs of the [14:09] nutritional deficiencies that we are [14:11] seeing in patients on these medications. [14:14] So, if that sounds of interest to you, [14:16] check that video out next. But thank you [14:17] guys so much for watching today's video [14:19] and if you enjoyed it, give it a thumbs [14:21] up, share it with your friends and as [14:22] always, don't forget sunscreen and [14:24] subscribe. I'll talk to you guys [14:25] tomorrow. Bye. [14:30] >> [music] [14:46] [music]